The #FDA has approved Sunharbo (asundexian) for adults with recent noncardioembolic ischemic stroke or high-risk TIA, in combination with antiplatelet therapy. In OCEANIC-STROKE, asundexian reduced ischemic stroke by 26% vs placebo, with similar overall major bleeding rates.
Read more:
https://t.co/SsavN2AU0O
@BayerUS #Stroke #IschemicStroke #TIA #SecondaryStrokePrevention #Neurology
New in Cephalalgia Reports!
A 69-year-old man with chronic cluster headache enjoyed a notable reduction in attack frequency with memantine 20 mg twice daily. Off-label use of memantine in cluster headache should be considered in select patients.
https://t.co/SRM6OGGzia
#migraine #headache #brain #pain #neurology #neuroscience
#STROKE: In a multicenter registry of patients with cerebral venous thrombosis, DOACs were noninferior to warfarin for preventing recurrent venous thromboembolism at 1 year. https://t.co/uCZNBKfeex
@amsterdamumc@AmsNeuroscience@VUamsterdam@UvA_Amsterdam